Lipoatrophia annularis

From WikiMD's Wellnesspedia

Lipoatrophia annularis is a rare, benign skin condition characterized by localized loss of subcutaneous fat. It was first described by Friedrich Schweninger and Paul Gerson Unna in 1898. The condition is also known as Schweninger-Buzzi anetoderma, Schweninger-Unna anetoderma, or anetoderma maculosa.

Symptoms and Signs[edit | edit source]

The primary symptom of Lipoatrophia annularis is the appearance of circular or oval depressions in the skin. These depressions are typically 1-2 cm in diameter and are often surrounded by a slightly raised border. The affected skin may appear normal or slightly discolored. The lesions are usually asymptomatic, but some patients may experience mild itching or discomfort.

Causes[edit | edit source]

The exact cause of Lipoatrophia annularis is unknown. Some researchers believe it may be related to an autoimmune response, while others suggest it could be a result of trauma or injury to the skin. There is also some evidence to suggest a genetic component, as the condition has been reported in multiple members of the same family.

Diagnosis[edit | edit source]

Diagnosis of Lipoatrophia annularis is typically based on the characteristic appearance of the skin lesions. In some cases, a skin biopsy may be performed to confirm the diagnosis and rule out other conditions.

Treatment[edit | edit source]

There is currently no cure for Lipoatrophia annularis, and treatment is primarily aimed at managing symptoms. Topical corticosteroids may be used to reduce inflammation and itching. In some cases, surgical intervention may be considered to improve the appearance of the skin.

See Also[edit | edit source]

References[edit | edit source]


Lipoatrophia annularis Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD